We are live on ! Find out more
VKTX icon

Viking Therapeutics
VKTX

422 hedge funds and large institutions have $5.25B invested in Viking Therapeutics in 2024 Q3 according to their latest regulatory filings, with 94 funds opening new positions, 179 increasing their positions, 101 reducing their positions, and 57 closing their positions.

New
Increased
Maintained
Reduced
Closed

92% more call options, than puts

Call options by funds: $464M | Put options by funds: $242M

77% more repeat investments, than reductions

Existing positions increased: 179 | Existing positions reduced: 101

65% more first-time investments, than exits

New positions opened: 94 | Existing positions closed: 57

33% more funds holding in top 10

Funds holding in top 10: 6 → 8 (+2)

23% more capital invested

Capital invested by funds: $4.26B → $5.25B (+$987M)

9% more funds holding

Funds holding: 387 → 422 (+35)

2.82% more ownership

Funds ownership: 72.94% → 75.76% (+2.8%)

Holders
422
Holders Change
+35
Holders Change %
+9.04%
% of All Funds
6.06%
Holding in Top 10
8
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+33.33%
% of All Funds
0.11%
New
94
Increased
179
Reduced
101
Closed
57
Calls
$464M
Puts
$242M
Net Calls
+$222M
Net Calls Change
-$14.8M

Top Buyers

1
Norges Bank
Norges Bank
Norway
+$63.8M
2
Citadel Advisors
Citadel Advisors
Florida
+$59M
3
IAIM
International Assets Investment Management
Florida
+$58.4M
4
PA
Perceptive Advisors
New York
+$57.4M
5
Morgan Stanley
Morgan Stanley
New York
+$54.4M

Top Sellers

1
Goldman Sachs
Goldman Sachs
New York
-$53.8M
2
BlackRock
BlackRock
New York
-$37.9M
3
Viking Global Investors
Viking Global Investors
Connecticut
-$37.1M
4
Millennium Management
Millennium Management
New York
-$32.3M
5
State Street
State Street
Massachusetts
-$26.3M
Name Holding Trade Value Shares
Change 		Change in
Stake
IC
426
Ikarian Capital
Texas
– -$7.33M -138,262 Closed
BOCH
427
Blue Owl Capital Holdings
New York
– -$5.57M -95,000 Closed
QIM
428
Quantitative Investment Management
Virginia
– -$4.48M -84,567 Closed
PP
429
Paloma Partners
Connecticut
– -$3.78M -71,266 Closed
Neuberger Berman Group
430
Neuberger Berman Group
New York
– -$3.75M -70,669 Closed
CC
431
Centiva Capital
New York
– -$3.59M -67,633 Closed
EAM
432
Eagle Asset Management
Florida
– -$3.62M -65,437 Closed
Mirae Asset Global ETFs Holdings
433
Mirae Asset Global ETFs Holdings
Hong Kong
– -$3.41M -64,820 Closed
BFM
434
Boothbay Fund Management
New York
– -$3.63M -61,790 Closed
PHS
435
PFM Health Sciences
California
– -$3.12M -58,811 Closed
TI
436
Trexquant Investment
Connecticut
– -$2.72M -51,296 Closed
QOP
437
Quinn Opportunity Partners
Virginia
– -$2.6M -49,000 Closed
Wellington Management Group
438
Wellington Management Group
Massachusetts
– -$2.11M -39,835 Closed
FC
439
FORA Capital
Florida
– -$1.65M -31,139 Closed
VF
440
Virtu Financial
New York
– -$1.46M -27,569 Closed
MAP
441
Moody Aldrich Partners
Massachusetts
– -$1.3M -24,465 Closed
PHP
442
Parkman Healthcare Partners
Connecticut
– -$1.08M -20,372 Closed
BHCM
443
Brevan Howard Capital Management
Jersey
– -$980K -18,489 Closed
ET
444
Entropy Technologies
New York
– -$755K -14,246 Closed
ProShare Advisors
445
ProShare Advisors
Maryland
– -$727K -13,716 Closed
PI
446
PEAK6 Investments
Illinois
– -$677K -11,546 Closed
AC
447
Aristides Capital
Kentucky
– -$583K -11,000 Closed
N
448
Natixis
France
– -$578K -10,900 Closed
WVP
449
Worth Venture Partners
New Jersey
– -$593K -10,100 Closed
HCM
450
Harvey Capital Management
Florida
– -$448K -8,450 Closed
16 17
18
19 20

VKTX Hedge Fund Activity: Q3 2024 in Review

422 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Viking Therapeutics (VKTX) for Q3 2024, worth a combined $5.25B — up 23% from $4.26B a quarter earlier.

Buyers outnumbered sellers: 94 funds opened new VKTX positions and 57 closed out — a net gain of 37 holders — while 179 added to existing stakes and 101 trimmed.

The largest buyer was Norges Bank, adding an estimated $63.8M. The largest seller was Goldman Sachs, cutting an estimated $53.8M.

  • 422 institutional investors held Viking Therapeutics (VKTX) as of Q3 2024, up from 387 in Q2 2024.
  • Funds reported $5.25B of Viking Therapeutics stock for Q3 2024, up 23% quarter-over-quarter.
  • 94 funds opened new Viking Therapeutics positions in Q3 2024 and 57 closed out, a net change of +37 holders.
  • The largest Viking Therapeutics buyer in Q3 2024 was Norges Bank, an estimated $63.8M added.
  • The largest Viking Therapeutics seller in Q3 2024 was Goldman Sachs, an estimated $53.8M sold.

Based on aggregated 13F filings for Q3 2024.